Market Currents
Life Sciences research firm Cambrex (CBM +13%) pops after its Q1 results easily topped Street...
-
Friday, May 4, 2012, 12:18 PM ETLife Sciences research firm Cambrex (CBM +13%) pops after its Q1 results easily topped Street estimates late yesterday. Overall revenue rose 14% Y/Y on higher sales of controlled substances and generic active pharmaceutical ingredients. The company also raises sales projections for FY12, now expecting sales to increase between 2% - 6% year-over-year.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
